ClinicalTrials.gg
Active, not recruitingNCT05407441Updated Apr 13, 2026

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

A Phase 1/2 interventional study of Tazemetostat and Nivolumab in Atypical Teratoid Rhabdoid Tumor, INI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors and SMARCA4-deficient Primary CNS Malignant Tumors, sponsored by Susan Chi, MD. Active, not recruiting at 3 sites in United States. Open to participants aged 6 Months to 21 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Susan Chi, MD · Phase 1/2, Interventional, and Treatment

How we know · 8 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
49
Allocation
Non-randomized
Ages
6 Months to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 103 studies in Rhabdoid Tumor with a site in United States — 18 open to participants now, 39 under way, none of them phase 3. Rhabdoid Tumor · United States.

Planned enrollment
28th of 92
49 · median 28
Started
2023
with 3 others
Phase 1/2
8 of 103
3 open now
Primary completion
2027-02
later than 18 of 38 live
Registered
90th of 103
by date

Among the 103 studies in Rhabdoid Tumor with a site in United States, this one is the 28th largest by planned enrollment of the 92 interventional ones that give a count, is one of 4 that started in 2023, is one of 8 in phase 1/2, reaches primary completion later than 18 of the 38 other live ones, and was the 90th registered.

Rhabdoid Tumor

115 studies on the registry are indexed under Rhabdoid Tumor; 23 are open to participants now.

Browse Rhabdoid Tumor studies →

Open to participants now

18 of the 103 studies in Rhabdoid Tumor with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Rhabdoid Tumor studies recruiting now, 2 (10%) set no upper age limit and 18 (90%) stop at 75 or younger; 20 take children under 18; none take healthy volunteers.

This study: 6 Months to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Rhabdoid Tumor with a site in United States, or all of them as a file.
02

Study summary

This research study involves a combination of three drugs given together as a possible treatment for malignant rhabdoid tumor, atypical teratoid rhabdoid tumor, epithelioid sarcoma, chordoma or other tumors that are deficient in one of two possible proteins, either INI-1 (SMARCB1) or SMARCA4.

The names of the study drugs involved in this study are:

  • Tazemetostat (TAZVERIK)
  • Nivolumab (OPDIVO)
  • Ipilimumab (YERVOY)
Read the detailed description

This research study involves a combination of three drugs given together as a possible treatment for these types of cancers. One drug is small molecule inhibitor targeting EZH2 (tazemetostat) and two are immunotherapeutic checkpoint inhibitors (nivolumab and ipilimumab). This is a Phase I/II clinical trial. Phase I clinical trials test the safety of an investigational drug, or combination of drugs, and tries to define the appropriate dose of the investigational drugs to use for further studies. Phase II clinical trials test the safety and effectiveness of an investigational drug, or drug combination, to learn whether the drug or drug combination works in treating a specific disease. "Investigational" means that the drug combination is being studied.

This trial is studying the combination of tazemetostat, nivolumab, and ipilimumab in two parts:

  • Part 1: To find the safest dose of these three study drugs in combination for children with INI1- (or SMARCA4-) negative cancers who have completed upfront treatment
  • Part 2: To determine whether this combination can effectively treat INI1- or SMARCA4-negative cancers

The research study procedures include screening for eligibility study treatment, evaluation and follow-up visits. Participants will be asked to provide blood samples and undergo procedures that might be different from a regular medical examination. There are additional research samples that participants will be asked to consent for their collection.

Participants will receive study treatment for up to 2 years, as long as there is benefit or there are no serious side effects. Participants will be followed for approximately 2 years after stopping treatment.

It is expected that about 49 people will take part in this research study.

The U.S. Food and Drug Administration (FDA) has not approved this combination of three drugs for this specific disease. However, tazemetostat has been approved for use in epithelioid sarcoma (an INI1-deficient tumor), and the combination of nivolumab and ipilimumab has also been approved for other uses. Separately, tazemetostat and the combination of nivolumab and ipilimumab have also been tested in children and the safest doses of each drug (and the combination for nivolumab and ipilimumab) have been determined.

Bristol-Myers Squibb and Epizyme, two pharmaceutical companies, are supporting this study by providing the study drugs. Dana-Farber Cancer Institute is also supporting this study by providing funding.

03

Conditions studied

  • Atypical Teratoid Rhabdoid Tumor
  • INI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors
  • SMARCA4-deficient Primary CNS Malignant Tumors
  • Malignant Rhabdoid Tumor (MRT)
  • Rhabdoid Tumor of the Kidney (RTK)
  • Epithelioid Sarcoma
  • Chordoma

Keywords

  • Atypical Teratoid Rhabdoid Tumor
  • INI1 (SMARCB1)-deficient primary CNS malignant tumors
  • SMARCA4-deficient primary CNS malignant tumors
  • Malignant rhabdoid tumor (MRT)
  • Rhabdoid Tumor of the Kidney (RTK)
  • Epithelioid Sarcoma
  • Chordoma
04

Who can participate

Ages eligible
6 Months to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis: confirmed tumors at diagnosis or at relapse (as applicable):
  • Stratum A

    • Atypical Teratoid Rhabdoid Tumor (ATRT)
    • Other INI1- or SMARCA4-deficient primary CNS malignant tumors (with PI approval)
  • Stratum B

    • Malignant rhabdoid tumor (MRT)
    • Rhabdoid tumor of the kidney (RTK)
    • Epithelioid sarcoma
    • Chordoma (poorly differentiated or de-differentiated)
    • Other INI1- or SMARCA4-deficient malignant tumors (with PI approval)
  • All subjects must have had tumor assessment at original diagnosis or relapse showing either of the following: Loss of INI1 confirmed by immunohistochemistry (IHC) OR molecular confirmation of tumor bi-allelic SMARCB1 (INI1) loss or mutation when INI1 IHC is equivocal or unavailable
  • Loss of SMARCA4 confirmed by IHC OR molecular confirmation of tumor SMARCA4 loss or mutation (with PI approval) Reports confirming these findings (including tumor sequencing if available) will be reviewed by the Sponsor-Investigator, PI or designee for approval of eligibility prior to enrollment.
  • Treatment status: All subjects must have completed planned upfront treatment for their disease for strata A1 or B1. Subjects need not have or have refractory disease to be eligible for this protocol.
  • Disease Status: For subjects under consideration for strata A1 or B1, subjects must have evaluable disease Note: lesions/disease are allowed as evaluable disease.
  • For relapsed/refractory subjects under consideration for strata A2 or B2, subjects must have as defined by RANO for stratum A2 or v1.1 for stratum B2. See Section 11.
  • Note: the following do not qualify as measurable disease:

    • malignant fluid collections (e.g., ascites, pleural effusions)
    • bone marrow infiltration
    • lesions only detected by nuclear medicine studies (e.g., bone, gallium or PET scans)
    • elevated tumor markers in plasma or CSF
    • previously irradiated lesions that have not demonstrated clear progression post- radiation therapy
    • leptomeningeal lesions that do not meet the measurement requirements for RANO.
  • For subjects under consideration for strata A3 or B3, subjects must have no evidence of evaluable or measurable disease by exam or imaging.
  • Pre-recurrent subjects to be enrolled in strata A1, B1, A3, or B3 must be enrolled within 8 weeks of completion of upfront therapy
  • Age ≥ 6 months and ≤ 21years of age
  • performance status ≥ 50% for subjects ≥16 years of age and Lansky performance status ≥ 50% for subjects \<16 years of age (see Appendix A). Note: Neurologic deficits in subjects with CNS tumors must have been stable for at least 7 days prior to study enrollment. Subjects who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
  • of greater than 2 months.
  • Prior Therapy: Subjects must have fully recovered from the acute toxic effects of all prior anti-cancer therapy. Subjects must meet the following minimum prior to first day of study treatment:

    • Myelosuppressive chemotherapy: ≥21 days after the last dose of myelosuppressive chemotherapy.
    • Anti-cancer agents not known to be myelosuppressive (e.g. not associated with reduced or ANC counts): ≥ 7 days after the last dose of the agent.
    • Small molecule biologic therapy: ≥7 days following the last dose of a non-monoclonal biologic agent.
    • Monoclonal antibody: ≥21 days after the last dose, and toxicity related to prior antibody therapy must be recovered to Grade ≤1.
    • : If used to modify immune adverse events related to prior therapy, ≥ 14 days must have elapsed since last dose of corticosteroid. CNS subjects receiving corticosteroids for neurologic symptom relief must be at stable or decreasing doses for at least 7 days prior to the first day of study treatment. For all patients, corticosteroid doses of up to 0.12 mg/kg/day prednisone equivalent may be approved after consultation with the Principal Investigator. Treatment with topical, inhaled or ophthalmic corticosteroid is acceptable.
  • Radiotherapy

    • ≥14 days after focal XRT (small port)
    • ≥90 days must have elapsed after prior TBI, craniospinal XRT or if >50% irradiation of pelvis
    • ≥42 days must have elapsed if other substantial bone marrow irradiation
    • ≥42 days must have passed since last radionuclide therapy (e.g. samarium or radium).
    • Myeloid growth factors: ≥14 days following the last dose of long-acting growth factor (e.g. Neulasta) or 7 days following short-acting growth factor.
    • Autologous stem cell therapy, Autologous T Cell, or other CellularTherapy: ≥ 42 days must have elapsed after any cellular therapy infusion. Prior stem cell transplant is not allowable.
    • Prior EZH2 inhibitor therapy: Subjects with relapsed/refractory disease (strata A2 and B2) may have received prior single agent tazemetostat or other EZH2 inhibitors for up to 1 year, but subjects without prior progression/relapse may NOT have received any prior EZH2 inhibitors.
  • Subjects must have adequate organ function as defined below:

    • Bone Marrow Function
    • ≥1,000/uL
    • ≥8 g/dL (may receive RBC transfusions)
    • Platelets: For non-relapsed subjects (Strata A1, A3, B1 or B3): >75K/uL, For subjects with relapsed disease (Strata A2 or B2): >50K/uL, For all subjects: must be platelet transfusion independent, defined as not receiving a platelet transfusion for at least 7 days prior to CBC documenting eligibility.
  • Hepatic Function

    • Total ≤ 1.5 x for age.
    • (SGPT) and AST (SGOT) ≤ 3 x upper limit of normal (for the purpose of this study, the ULN for ALT is 45 U/L)
  • Renal Function: A serum creatinine based on age/gender as follows: Maximum Serum Creatinine (mg/dL)

    • Male: 6 months to 1 year-0.5,1 to \< 2 years-0.6, 2 to \< 6 years-0.8, 6 to \< 10 years-1, 10 to \< 13 years-1.2,13 to \< 16 years- 1.5, ≥ 16 years 1.7
    • Female: 6 months to 1 year-0.5,1 to \< 2 years-0.6, 2 to \< 6 years-0.8, 6 to \< 10 years-1, 10 to \< 13 years-1.2,13 to \< 16 years- 1.4, ≥ 16 years1.4 OR
    • ≥ 70 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal.
  • Adequate Pulmonary Function defined as: No evidence of dyspnea at rest, no exercise intolerance due to pulmonary insufficient and a pulse oximetry > 92% while breathing room air.

    -- Adequate Neurologic Function defined as: Subjects with seizure disorder may be enrolled if on anticonvulsants and well controlled. Nervous system disorders ( v5.0) resulting from prior therapy must be ≤ Grade 2, with the exception of decreased tendon reflex (DTR). Any grade of DTR is eligible.

  • Negative B-HCG pregnancy test (urine or serum) in females of .
  • Women of childbearing potential (WOCBP) receiving the TAZNI combination agree to adhere to for a period of 5 months after the last dose of either tazemetostat, nivolumab, or ipilimumab
  • Men receiving the TAZNI combination and who are sexually active with WOCBP will agree to adhere to barrier contraception for a period of 3 months after the last dose of either tazemetostat, nivolumab or ipilimumab.
  • Ability to understand and/or the willingness of the subject (or parent or legally authorized representative, if minor) to provide , documented using an institutionally approved informed consent procedure.

Exclusion criteria

Exclusion Criteria:

  • Concomitant Medications
  • Subjects who are receiving any other agents or other anti-cancer agents are not eligible.
  • Agents: Subjects who are currently receiving drugs that are strong or moderate inducers or inhibitors of CYP3A4 are not eligible. Such inducers or inhibitors of CYP3A4 are prohibited from 14 days prior to the first dose of tazemetostat to the end of the study. See Appendix C for a list of agents. Note:Dexamethasone for CNS tumors or , on a stable or decreasing dose, is allowed up to 0.12mg/kg/day prednisone equivalents.
  • Subjects with a known history of , , and/or (testing not required as part of screening).
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or any other concurrent disease which in the judgment of the Investigator would make the subject inappropriate for enrollment on this study.
  • Has a history of (non-infectious) pneumonitis that required or has current pneumonitis.
  • Has active disease that has required systemic treatment in the past 12 months, or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or agents. Subjects with vitiligo or resolved childhood asthma/atopy are exceptions. Intermittent use of bronchodilators or local steroid injections are not excluded. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Autoimmune diagnoses not listed must be approved by the Principal Investigator.
  • On screening CBC differential, subjects must not have any significant morphologic abnormalities concerning for MPN/MDS or ALL.
  • Subjects must not have any prior history of myeloid , including myelodysplastic syndrome (MDS) or prior history of lymphoblastic lymphoma (LBL) or leukemia (ALL).
  • Subjects who have received prior solid organ transplantation are not eligible.
  • Pregnancy or Breast-Feeding: Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as there is yet no available information regarding human fetal or teratogenic toxicities.
  • Has received prior therapy with an , anti-PD-L1, anti-PD-L2 or anti-CTLA4 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. OX40, CD137).
  • Subjects who have received live / attenuated vaccine within 30 days of first dose of study treatment.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to tazemetostat or Orasweet.
  • Subjects who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study are not eligible.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
49 participants (estimated)

Study arms

  • Experimental
    Phase I a: DOSE ESCALATION (STRATUM A, ATRT and primary CNS malignant tumor, INI/SMARCA4-deficient)

    Part 1 will be two concurrent "rolling six" phase 1 studies starting at a different tazemetostat dose for each stratum), with one dose escalation and one dose de-escalation planned. All subjects will receive the same nivolumab and ipilimumab doses and dosing schedule

    Drug: Tazemetostat · Drug: Nivolumab · Drug: Ipilimumab

  • Experimental
    Phase I b: DOSE ESCALATION (STRATUM B, NON-ATRT, NON-CNS)

    Part 1 will be two concurrent "rolling six" phase 1 studies starting at a different tazemetostat dose for each stratum), with one dose escalation and one dose de-escalation planned. All subjects will receive the same nivolumab and ipilimumab doses and dosing schedule

    Drug: Tazemetostat · Drug: Nivolumab · Drug: Ipilimumab

  • Experimental
    EXP A1: TAZEMETOSTAT + NIVOLUMAB + IPILIMUMAB DOSE EXPANSION (SUBSTRATA A1)

    Once the MTD or RP2D of the combination is determined for each stratum, the Part 2 portion will open for that stratum, with subjects from Part 1 who are treated at the RP2D to be counted towards the enrollment numbers for Part 2. Part 2 will consist of 3 substrata per stratum based on their disease status

    Drug: Tazemetostat · Drug: Nivolumab · Drug: Ipilimumab

  • Experimental
    EXP A2: TAZEMETOSTAT + NIVOLUMAB + IPILIMUMAB DOSE EXPANSION (SUBSTRATA A2)

    Once the MTD or RP2D of the combination is determined for each stratum, the Part 2 portion will open for that stratum, with subjects from Part 1 who are treated at the RP2D to be counted towards the enrollment numbers for Part 2. Part 2 will consist of 3 substrata per stratum based on their disease status

    Drug: Tazemetostat · Drug: Nivolumab · Drug: Ipilimumab

  • Experimental
    EXP A3: TAZEMETOSTAT + NIVOLUMAB + IPILIMUMAB DOSE EXPANSION (SUBSTRATA A3)

    Once the MTD or RP2D of the combination is determined for each stratum, the Part 2 portion will open for that stratum, with subjects from Part 1 who are treated at the RP2D to be counted towards the enrollment numbers for Part 2. Part 2 will consist of 3 substrata per stratum based on their disease status

    Drug: Tazemetostat · Drug: Nivolumab · Drug: Ipilimumab

  • Experimental
    EXP B1: TAZEMETOSTAT + NIVOLUMAB + IPILIMUMAB DOSE EXPANSION (SUBSTRATA B1)

    Once the MTD or RP2D of the combination is determined for each stratum, the Part 2 portion will open for that stratum, with subjects from Part 1 who are treated at the RP2D to be counted towards the enrollment numbers for Part 2. Part 2 will consist of 3 substrata per stratum based on their disease status

    Drug: Tazemetostat · Drug: Nivolumab · Drug: Ipilimumab

  • Experimental
    EXP B2: TAZEMETOSTAT + NIVOLUMAB + IPILIMUMAB DOSE EXPANSION (SUBSTRATA B2)

    Once the MTD or RP2D of the combination is determined for each stratum, the Part 2 portion will open for that stratum, with subjects from Part 1 who are treated at the RP2D to be counted towards the enrollment numbers for Part 2. Part 2 will consist of 3 substrata per stratum based on their disease status

    Drug: Tazemetostat · Drug: Nivolumab · Drug: Ipilimumab

  • Experimental
    EXP B3: TAZEMETOSTAT + NIVOLUMAB + IPILIMUMAB DOSE EXPANSION (SUBSTRATA B3)

    Once the MTD or RP2D of the combination is determined for each stratum, the Part 2 portion will open for that stratum, with subjects from Part 1 who are treated at the RP2D to be counted towards the enrollment numbers for Part 2. Part 2 will consist of 3 substrata per stratum based on their disease status

    Drug: Tazemetostat · Drug: Nivolumab · Drug: Ipilimumab

Interventions

  • oral, twice daily, dosage per protocol

    Also known as: TAZVERIK

  • IV, dosage and schedule per protocol

    Also known as: OPDIVO

  • IV, dosage and schedule per protocol

    Also known as: YERVOY

06

What researchers measure

Primary outcomes

  1. Incidence of Grade 3 or Higher Treatment-Related Toxicity

    All grade 3 or higher adverse events (AE) with treatment attribution of possibly, probably or definite based on CTCAE v5 as reported on case report forms will be counted. Incidence is the number of patients experiencing at least one treatment-related grade 3 or higher AE of any type during the time of observation.

    Time frame: AE to be collected continuously after the patient has provided informed consent through up to 30 days after last dose of study treatment up to 5.5 years

  2. Maximal Tolerated Dose (MTD)

    The MTD defined as the dose level associated with observed DLTs in \<33% of enrolled subjects. The DLT assessment will be restricted to the first cycle.

    Time frame: Treatment duration is a median of N cycles range (t1 - t2). Treatment continues until disease progression or unacceptable toxicity up to 5.5 years

Secondary outcomes

  1. Recommended Pediatric Phase 2 Dose (RP2D)

    Time frame: Treatment duration is a median of N cycles range (t1 - t2). Treatment continues until disease progression or unacceptable toxicity up to 5.5 years

  2. Overall Response Rate (ORR)

    The objective response rate (ORR) is defined as the proportion of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 or RANO criteria on treatment. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions.

    Time frame: Disease is evaluated each cycle on treatment; Treatment continued until disease progression or unacceptable toxicity. Treatment duration was a median of N cycles range (t1 - t2) up to 5.5 years

  3. Median Overall Survival (OS)

    OS based on the Kaplan-Meier method is defined as the time from study entry to death or censored at date last known alive.

    Time frame: Up through 5.5 years

  4. Median Progression-free survival (PFS)

    Progression-free survival based on the Kaplan-Meier method is defined as the duration of time from study entry to documented disease progression (PD) or death. Per RECIST 1.1 criteria: progressive disease (PD) is at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. PD for the evaluation of non-target lesions is the appearance of one or more new lesions and/or unequivocal progression of non-target lesions.

    Time frame: Participants are followed for survival every 6 months, up to 3 years after treatment discontinuation

07

Study locations

3 sites
08

References and documents

Publications

  • Roden AC. Molecularly Defined Thoracic Neoplasms. Adv Anat Pathol. 2024 Sep 1;31(5):303-317. doi: 10.1097/PAP.0000000000000439. Epub 2024 Mar 19. PubMed 38501690 ↗

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2023 (actual). Primary completion is estimated for Feb 2027, 41 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2022
First posted
Jun 7, 2022
StartActual
Aug 10, 2023
Primary completionEst.
Feb 1, 2027
CompletionEst.
Feb 1, 2029
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05407441
Lead sponsor
Susan Chi, MD
Responsible party
Susan Chi, MD (Sponsor Investigator, Dana-Farber Cancer Institute) — Sponsor-investigator
First posted
Jun 7, 2022
Start date
Aug 10, 2023
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 1, 2029 (estimated)
Last update
Apr 13, 2026

Study contacts

Susan Chi, MD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tazemetostat · Nivolumab

Start the discussion